Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 2/20 | 0.36 |
| ▸ | GOPC | Q9HD26 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6839496 | 0.73 | USP8 (0.35) | ALDH1A1GAA | |
| SCHEMBL7185897 | 0.71 | SLC6A4 (0.48) | NPC1RAB9ALMNAALDH1A1MAPT | |
| SCHEMBL6843937 | 0.71 | SLC6A4 (0.48) | NPC1RAB9ALMNAALDH1A1MAPT | |
| SCHEMBL15596503 | 0.70 | P2RY14 (0.42) | — | |
| SCHEMBL14704704 | 0.70 | P2RY14 (0.42) | — | |
| SCHEMBL15596271 | 0.70 | P2RY14 (0.42) | — | |
| SCHEMBL16941423 | 0.70 | P2RY14 (0.42) | — | |
| SCHEMBL24923905 | 0.70 | BRD4 (0.36) | — | |
| SCHEMBL16941409 | 0.68 | CHRNA7 (0.41) | — | |
| SCHEMBL24923554 | 0.68 | CHRNA7 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6372762-B1 | HETEROCYCLIC COMPOUNDS FOR NERVOUS SYSTEM DISORDERS | PFIZER INC. | 2002-04-16 | — | — | US | disclosed |
| US-20020019401-A1 | Substituted bicyclic derivatives for treating central nervous system disorders | FLIRI ANTON FRANZ JOSEPH (US) | 2002-02-14 | — | — | US | disclosed |
| EP-0953567-A2 | Bicyclic substituted piperazine-, piperidine- and tetrahydropyridine derivatives, their preparation and their use as agents with central dopaminergic (dopamine D4 receptor) activity | Pfizer Products Inc. (US) | 1999-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019401-A1 | Substituted bicyclic derivatives for treating central nervous system disorders | OPRK1, OPRD1, MC2R | CFTR 3174/4885GOPC 3094/4885NPC1 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.